The data base below lists known point mutations and short deletions and additions in the factor IX gene, which cause the bleeding disorder haemophilia B or Christmas disease (for reviews, see Brownlee 1988 , Giannelli 1989 , Thompson 1990 . Mutations result in defective clotting factor EX-a 415 aminoacid-long glycoprotein normally present in plasma and an essential component of the middle phase of the intrinsic clotting cascade. The disease is a rare, inherited, X-linked recessive disorder affecting 1 in about 30,000 males and only very rarely females.
The purpose of this database is to update last year's one (Giannelli et al, 1990 ) by collecting in an accessible, summary form, molecular data on the causative mutations of haemophilia B patients worldwide. It is not intended to replace primary publications although it does contain a significant amount of unpublished work. Because haemophilia B is a disease with a relatively high de novo mutation rate, it has been thought for many years that a wide spectrum of mutations covering many parts of the gene would cause disease. This database amply demonstrates this, but also highlights nucleotides where there are mutation hotspots, because we have included not only molecularly unique mutations, but also repeat observations of the same mutation.
Because of the vast rate of increase in knowledge in this field since the first point mutation, 'Chapel Hill', was named and characterized in 1983 (Noyes et al, 1983) , there has been controversy as to how to name a large number of patients in an anonymous way suitable for publication, and indeed a variety of differing conventions have been favoured by different investigators (see main Table) . In an attempt to simplify the present situation, we introduce here a simple numerical nomenclature which we refer to as a Patient Identity Number, or PEN number. Thus, in this database, patients have PEN numbers ranging from 1 to 388. We hope that this new system will be accepted by all workers in this field and that the definitive PEN number now assigned to a given patient or pedigree will coexist with the existing nomenclature (if any) contained within the original reference.
The factor EX gene lies on the long arm of the X chromosome at Xq27 and its entire sequence of 33 kb is known (Yoshitake et al, 1985) . It contains 8 exons (a-h) encoding 6 major domains of factor EX. These are: (1) exon a-a hydrophobic signal peptide which targets the protein for secretion from the hepatocyte into the blood stream. (2) exons b and c-a propeptide and gla domain,-the latter containing 12 7-carboxyglutamyl residues. This post-translational modification is required for the correct folding and calcium binding of factor EX. (3) exon d-a type B, or first epidermal growth factor-like domain, which shows homology to epidermal growth factor (EGF) and, in addition, contains conserved carboxylate residues including a /3-hydroxyaspartate at amino acid 64. This domain binds an additional Ca 2 * with high affinity (Handford et al, 1990) . (4) exon e-a type A, or second epidermal growth factor-like (EGF) domain which lacks the conserved carboxylate residues of the EGF type B domain. (5) exon f-an activation domain, within which factor XIa cleaves twice, converting factor EX to EXa; (6) exons g and h-the serine protease or catalytic domain, responsible for the proteolysis of factor X to Xa. This region is homologous to other well studied serine proteases (e.g. chymotrypsin) and it is thought likely that his (221), asp (269) and ser (365), all participate in the classical catalytic mechanism.
Factor EX is initially synthesised in the liver as a precursor molecule, either 46, 41 or 39 amino acids (it is not known which, although 39 is probable (Pang et al, 1990 )) longer at its Nterminus than the 415-long mature factor EX found in plasma.
• To whom correspondence should be addressed Processing steps occur in the hepatocyte prior to secretion and sequentially remove the hydrophobic signal peptide and the propeptide. In addition to the 7-carboxylation of the 12 N-terminal glutamyl residues carried out by a vitamin K-dependent carboxylase, and the partial /9-hydroxylation of aspartate 64, Nlinked carbohydrate side chains are added at residues 157 and 167 and at least an O-linked carbohydrate at serine 53.
There are 397 entries in this second edition of the database compared with 221 last year (Giannelli et al, 1990) . Besides point mutants, it includes 40 short (defined as less than 20 nucleotides) deletions or additions or both, made up from 31 deletions, 6 additions and 3 examples involving both additions and deletions. There are also 9 double mutations, 8 inhibitor patients and 1 female haemophiliac, presumably caused by non-random Xinactivation. The list excludes 29 patients with partial or complete gene deletions or more complex rearrangements (Thompson, 1990) . Of the 388 patients studied (see Summary Table) , 206 are unique molecular events, the remainder being repeats. As is well known, many (and here, 132 or 72%) of these repeats occur at CG doublets and involve a CG -TG or CA change. As discussed before (Giannelli et al, 1990) , such mutants are believed to be genuine 'hotspots' for mutation (although the independent origin of identical mutations has not been demonstrated in every case), because of methylation of cytosine to 5' methylcytosine. This modified cytosine is amongst the more unstable residues in DNA and deaminates giving rise to thymine, in either the coding or non-coding strand of the gene. For example, nucleotide 31,008 is represented 19 times in the database and 6 other mutations involving nucleotides within CG doublets are reported 10 times or more. We calculate from the database that 39% (or 151 of the total of 388 mutations) occur at CG doublets. The remaining 28% repeat mutations do not involve CG mutations, but these cases generally occur twice or three times only in the database. They may, in some cases, represent genuine independent mutations. However, we suspect a majority are the same 'founder' mutation in related pedigrees. An exception to the 'rule' that multiple repeat mutations are confined to CG doublets are the 19 reported mutants at nucleotide 31,311. Thompson etal (1990) have proposed from ahaplotype analysis that these represent a single 'founder' mutant which, for unknown reasons, has become, atypically, widely distributed.
There is probably some explanation other than chance for the few, atypical, cases where CG mutants are rare, occurring only once, twice or three times (e.g. nucleotides 17,761, -6 and 6,461, respectively) . We propose that non-methylation or partial methylation of the cytosine in the CG doublet could explain the 17,761 and -6 observations, whilst the low frequency of mutations at 6,461 might be due to the extremely mild nature of the disease (-30% clotting activity) caused by this particular mutation (R->Q at amino acid 29) resulting in an under-reporting of this mutation.
The distribution of mutants according to protein domains and control regions within the gene (see Summary Table) shows that mutations have been detected in all categories listed except the poly(A) site. Missense mutations within individual protein domains give valuable information as to the essential nature of specific amino acids and are a significant aid to structural studies of domains (e.g. see Handford et al, 1990) . Similarly, promoter mutations are invaluable in studying gene regulation (e.g. Crossley & Brownlee, 1990) .
The only other specific group of inherited diseases with a comparable number of characterized mutations as in haemophilia B are the haemoglobinopathies. They are caused mostly by point mutations in the a or /3-globin locus, and over 150 molecularly unique mutations are known (Winslow & Anderson, 1983) . In addition, there are more than 50 non-deletion mutations causing a-or /3-thalassaemia, affecting the globin genes (Thein & Weatherall, 1988) .
The data base was compiled from separate lists updating the previous year's list prepared by coordinators for the different countries as follows:-Giannelli and Green representing the UK, Sweden and Iceland (70 new entries); High and Sommer representing USA (58 new entries); Lillicrap representing Canada (11 new entries); Ludwig and Olek representing Germany (29 new entries); Reitsma representing The Netherlands (no new entries); Goossens representing France (1 new entry); Yoshioka representing Japan (1 new entry); and Brownlee, the rest of the world (7 new entries) and central coordinator. We plan to update this data base annually. New data or notification of errors or omissions should be sent to the individual country coordinators by 31st December 1991. This database is available from individual country coordinators on floppy discs written in Wordperfect 5.1 on an IBM PS2 computer. We hope to generate a new-style database by 1992 which will be held on the EMBL DataLibrary file server in Heidelberg, Germany, in a form which can be retrieved directly from them by electronic mail. 6,326-6,375 6,376-6,489 6,678-6,701 10,392-10,505 17,669-17,797 20,363-20,565 30,039-30,153 30,822-31,372 Number of mutants Gastel   10   14  1  19  <l  11   10-12   10  12  26  <1  <1  1  14  10  13  12   100  80  90  108   114  58  49  <30  52  <1  2  11  34  31 50, Q->P 55, P-»A 55, P->A 55, P->A 55, P->S 55, P->L 56, C->R 56, C-»S 56, C->Y 60, G^S 60, G->S 60, G-^S 
